Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Jiangsu Recbio Technology Co., Ltd.
江蘇瑞科生物技術股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2179)

VOLUNTARY ANNOUNCEMENT

ACCEPTANCE OF THE NEW DRUG APPLICATION FOR THE COMPANY'S NOVEL ADJUVANTED RECOMBINANT SHINGLES VACCINE REC610 BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

This announcement is made by Jiangsu Recbio Technology Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on voluntary basis.

The board of directors of the Company (the "**Board**") is pleased to announce that in recent days, the new drug application for the Company's novel adjuvanted recombinant shingles vaccine REC610 ("**REC610**") has been officially accepted by the Center for Drug Evaluation of the National Medical Products Administration, with the acceptance number being CXSS2500145.

Shingles is a common disease caused by a latent infection of the virus, patients may develop post-herpetic neuralgia (PHN), this intense nerve pain seriously damage the patient's health and affect the quality of life of patients. According to statistics, about 6 million new cases of shingles occur each year in China, and the patients of shingles have gradually become younger in recent years. According to global research data on shingles vaccines that have been marketed, as compared to attenuated live vaccines, novel adjuvanted recombinant shingles vaccines can provide stronger cellular immunity, better efficacy and longer protection period. REC610 is equipped with a novel adjuvant BFA01 independently developed by the Company, which can promote the production of high levels of VZV glycoprotein E(gE)-specific CD4 + T cells and antibody. Currently, only GlaxoSmithKline's Shingrix®, the novel adjuvant recombinant vaccine, is on the market across the globe.

The Company has received a drug clinical trial approval notice issued by the National Medical Products Administration in October 2023 for REC610 (Notice No.: 2023LP02151), and has completed the enrollment of all subjects of the phase III clinical trial in December 2024. Currently, we are performing follow-up visits and observation procedures in accordance with the clinical protocol. This study is a randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy, safety and immunogenicity of REC610 in healthy subjects aged 40 years and above.

The Company conducted Shingrix® parallel controlled exploratory clinical trial in the Philippines and China, respectively, both achieving expected results. Data showed that REC610 had overall good safety profile with the 2-dose vaccination regimen in healthy subjects aged 40 and above. No serious adverse event (SAE), adverse event of special interest (AESI) related to vaccination for research purposes or treatment emergent adverse event (TEAE) was observed. REC610 induced strong gE-specific cellular immune responses, which were comparable between REC610 and Shingrix® group.

Shareholders and potential investors should note that the Group may not develop or market REC610 successfully and should exercise caution when dealing in the securities of the Company.

By order of the Board
Jiangsu Recbio Technology Co., Ltd.
Mr. XU Haoyu
Chairman

Jiangsu Province, the PRC, December 29, 2025

As at the date of this announcement, the Board comprises Mr. XU Haoyu as the Chairman of the Board and a non-executive director, Dr. LIU Yong, Mr. WEI Qifang and Ms. WANG Jing as executive directors, Dr. WANG Ruwei, Dr. ZHANG Jiaxin, Dr. ZHOU Hongbin and Mr. HU Houwei as non-executive directors, and Dr. XIA Lijun, Mr. LIANG Guodong, Professor GAO Feng and Professor YUEN Ming Fai as independent non-executive directors.